Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer

Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the f...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 20; no. 1; pp. 1 - 13
Main Authors Wang, Zhan, Wang, Miao-Miao, Geng, Yan, Ye, Chen-Yang, Zang, Yuan-Sheng
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 05.09.2022
BioMed Central
BMC
Subjects
Online AccessGet full text
ISSN1479-5876
1479-5876
DOI10.1186/s12967-022-03608-z

Cover

Loading…
Abstract Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. Keywords: Colorectal cancer, Membrane-associated RING-CH protein 8 (MARCH8), Glycolysis, HK2, miR-32
AbstractList Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC.BACKGROUNDColorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC.In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed.METHODIn this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed.Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression.RESULTSSystematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression.In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC.CONCLUSIONIn summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC.
Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC.
Abstract Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC.
Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. Keywords: Colorectal cancer, Membrane-associated RING-CH protein 8 (MARCH8), Glycolysis, HK2, miR-32
Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC.
ArticleNumber 402
Audience Academic
Author Zang, Yuan-Sheng
Ye, Chen-Yang
Wang, Zhan
Wang, Miao-Miao
Geng, Yan
Author_xml – sequence: 1
  givenname: Zhan
  surname: Wang
  fullname: Wang, Zhan
– sequence: 2
  givenname: Miao-Miao
  surname: Wang
  fullname: Wang, Miao-Miao
– sequence: 3
  givenname: Yan
  surname: Geng
  fullname: Geng, Yan
– sequence: 4
  givenname: Chen-Yang
  surname: Ye
  fullname: Ye, Chen-Yang
– sequence: 5
  givenname: Yuan-Sheng
  surname: Zang
  fullname: Zang, Yuan-Sheng
BookMark eNp9kktrGzEUhYeS0jzaP9CVoJt0MamkGb02BWPa2JC0YNq10GjuuDIzI1eSA86vryZOSB1K0ULi6pzvci_nvDgZ_QhF8Z7gK0Ik_xQJVVyUmNISVxzL8v5VcUZqoUomBT_5631anMe4wZjWrFZvitOs5rXA_KxItzA0wYxQmhi9dSZBi1bLb9flfIG2wSdwI7q8na3mC_kRuYgMGv0d9Gjd763v9zGXAmwDZHdAyYQ1TIRmjwa3KiuKsj3rfACbTI-sGS2Et8XrzvQR3j3eF8XPr19-zBflzffr5Xx2U1pW41RSaXErLW-tsZK1LekqAg1jqpGCtbhSUHHVEaYwKMVYR7ExkjdAORWC87a6KJYHbuvNRm-DG0zYa2-cfij4sNYmJGd70FK1nMkGM8aqmlojm8pQajkmjeKMQGZ9PrC2u2aA1sKYgumPoMc_o_ul1_5Oq7rmQtQZcPkICP73DmLSg4sW-j4v3--ipoJgJSpS0Sz98EK68bsw5lVNKsYIxYQ9q9YmD-DGzue-doLqmSCcMqrY1PbqH6p8WhiczYHqXK4fGeTBYIOPMUCnrUsmOT-N5XpNsJ7Spw_p0zl9-iF9-j5b6Qvr03r-Y_oD5-va9A
CitedBy_id crossref_primary_10_1186_s10020_023_00684_9
crossref_primary_10_1007_s12291_023_01175_8
crossref_primary_10_1186_s13578_023_01100_9
crossref_primary_10_3390_v16121935
crossref_primary_10_1016_j_prp_2025_155909
crossref_primary_10_1186_s12943_024_02046_3
crossref_primary_10_1007_s10555_024_10201_x
crossref_primary_10_3892_mmr_2025_13441
Cites_doi 10.1016/j.nbt.2016.12.002
10.1371/journal.pone.0001852
10.18632/oncotarget.22602
10.1074/jbc.RA119.007508
10.1007/s00432-020-03172-3
10.1016/j.jprot.2021.104125
10.1038/onc.2017.31
10.1002/ijc.32104
10.3322/caac.21338
10.1038/s41467-019-10374-y
10.3390/cancers12061655
10.1159/000492882
10.1016/j.biopha.2018.07.050
10.1111/j.1743-7563.2012.01535.x
10.1084/jem.20160312
10.1016/j.cmet.2015.12.006
10.1038/nature07385
10.1016/S0140-6736(19)32319-0
10.18632/oncotarget.19658
10.1074/jbc.M112.448209
10.1007/s11626-019-00398-5
10.1001/jama.2021.0106
10.3892/ol.2012.928
10.2147/OTT.S228995
10.1002/ijc.32084
10.1038/oncsis.2017.57
10.1093/jnci/djz093
10.1074/jbc.M211285200
10.1002/ijc.33725
10.1186/s12935-017-0490-y
10.3322/caac.21590
10.1038/nchembio.971
10.1073/pnas.1205246109
10.1186/1476-4598-12-30
10.1016/j.cell.2012.02.065
10.3390/cancers13112550
10.3390/jcm9082419
10.1038/cr.2016.159
10.3389/fonc.2019.01207
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12967-022-03608-z
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 13
ExternalDocumentID oai_doaj_org_article_89d658b0555342ca8b3a22c601b9651e
PMC9446774
A716252954
10_1186_s12967_022_03608_z
GeographicLocations China
United States--US
GeographicLocations_xml – name: China
– name: United States--US
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-28c0d8c6dcac85dd1f31eb559b875d039e369f1590e9955f20aa86be2627766d3
IEDL.DBID M48
ISSN 1479-5876
IngestDate Wed Aug 27 01:23:46 EDT 2025
Thu Aug 21 13:41:36 EDT 2025
Fri Jul 11 01:14:04 EDT 2025
Fri Jul 25 02:25:34 EDT 2025
Tue Jun 17 21:11:14 EDT 2025
Tue Jun 10 20:50:30 EDT 2025
Tue Jul 01 02:59:36 EDT 2025
Thu Apr 24 22:59:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-28c0d8c6dcac85dd1f31eb559b875d039e369f1590e9955f20aa86be2627766d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-022-03608-z
PMID 36064706
PQID 2715512015
PQPubID 43076
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_89d658b0555342ca8b3a22c601b9651e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9446774
proquest_miscellaneous_2710973132
proquest_journals_2715512015
gale_infotracmisc_A716252954
gale_infotracacademiconefile_A716252954
crossref_citationtrail_10_1186_s12967_022_03608_z
crossref_primary_10_1186_s12967_022_03608_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-05
PublicationDateYYYYMMDD 2022-09-05
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-05
  day: 05
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of translational medicine
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References R Mclendon (3608_CR19) 2008; 455
T Ye (3608_CR28) 2019; 55
G Yang (3608_CR29) 2019; 9
W Wu (3608_CR30) 2013; 12
S Singh (3608_CR11) 2017; 17
J Liu (3608_CR44) 2020; 146
H Liang (3608_CR27) 2019; 12
J Yin (3608_CR36) 2018; 49
W Chen (3608_CR3) 2016; 66
NN Pavlova (3608_CR4) 2016; 23
R Chen (3608_CR24) 2012; 109
LH Biller (3608_CR9) 2021; 325
E Chen (3608_CR26) 2018; 106
I Cristobal (3608_CR31) 2020
HJ Lee (3608_CR42) 2019; 10
A Bar-Even (3608_CR23) 2012; 8
N Guo (3608_CR25) 2013; 9
J Fan (3608_CR35) 2017; 8
RL Siegel (3608_CR2) 2020; 70
Q Wang (3608_CR14) 2017; 6
F Chiara (3608_CR43) 2008; 3
J Yin (3608_CR13) 2018; 49
C Zhang (3608_CR16) 2019; 23
J Fan (3608_CR12) 2017; 8
LAM Cornelissen (3608_CR7) 2019; 144
J Liang (3608_CR22) 2017; 27
N Papadimitriou (3608_CR6) 2021; 149
AJ Franke (3608_CR8) 2019; 111
H Liu (3608_CR34) 2016; 213
R Myte (3608_CR5) 2019; 145
J Zheng (3608_CR37) 2012; 4
W Chen (3608_CR17) 2021
A Floridi (3608_CR20) 1981; 66
E Goto (3608_CR33) 2003; 278
E Dekker (3608_CR1) 2019; 394
S Singh (3608_CR15) 2021; 236
J Bauer (3608_CR10) 2017; 38
I Cristobal (3608_CR32) 2020
Y Shang (3608_CR39) 2017; 36
H Fujita (3608_CR40) 2013; 126
CH Chan (3608_CR38) 2012; 149
B van de Kooij (3608_CR41) 2013; 288
Y Li (3608_CR21) 2019; 294
X Zhang (3608_CR18) 2017; 8
References_xml – volume: 38
  start-page: 7
  year: 2017
  ident: 3608_CR10
  publication-title: N Biotechnol
  doi: 10.1016/j.nbt.2016.12.002
– volume: 66
  start-page: 497
  year: 1981
  ident: 3608_CR20
  publication-title: J Natl Cancer Inst
– volume: 3
  start-page: e1852
  year: 2008
  ident: 3608_CR43
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0001852
– volume: 8
  start-page: 108238
  year: 2017
  ident: 3608_CR12
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.22602
– volume: 294
  start-page: 14745
  year: 2019
  ident: 3608_CR21
  publication-title: J Biol Chem
  doi: 10.1074/jbc.RA119.007508
– volume: 146
  start-page: 809
  year: 2020
  ident: 3608_CR44
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-020-03172-3
– volume: 236
  start-page: 104125
  year: 2021
  ident: 3608_CR15
  publication-title: J Proteomics
  doi: 10.1016/j.jprot.2021.104125
– volume: 8
  start-page: 108238
  year: 2017
  ident: 3608_CR35
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.22602
– volume: 36
  start-page: 4191
  year: 2017
  ident: 3608_CR39
  publication-title: Oncogene
  doi: 10.1038/onc.2017.31
– volume: 145
  start-page: 327
  year: 2019
  ident: 3608_CR5
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32104
– volume: 66
  start-page: 115
  year: 2016
  ident: 3608_CR3
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21338
– volume: 10
  start-page: 2625
  year: 2019
  ident: 3608_CR42
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-10374-y
– year: 2020
  ident: 3608_CR32
  publication-title: Cancers
  doi: 10.3390/cancers12061655
– volume: 49
  start-page: 306
  year: 2018
  ident: 3608_CR13
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000492882
– volume: 106
  start-page: 1046
  year: 2018
  ident: 3608_CR26
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2018.07.050
– volume: 9
  start-page: 6
  year: 2013
  ident: 3608_CR25
  publication-title: Asia Pac J Clin Oncol
  doi: 10.1111/j.1743-7563.2012.01535.x
– volume: 213
  start-page: 1695
  year: 2016
  ident: 3608_CR34
  publication-title: J Exp Med
  doi: 10.1084/jem.20160312
– volume: 23
  start-page: 27
  year: 2016
  ident: 3608_CR4
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2015.12.006
– volume: 49
  start-page: 306
  year: 2018
  ident: 3608_CR36
  publication-title: Cellular Physiol Biochem
  doi: 10.1159/000492882
– volume: 455
  start-page: 1061
  issue: 7216
  year: 2008
  ident: 3608_CR19
  publication-title: Nature
  doi: 10.1038/nature07385
– volume: 394
  start-page: 1467
  year: 2019
  ident: 3608_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32319-0
– volume: 8
  start-page: 82593
  year: 2017
  ident: 3608_CR18
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19658
– volume: 288
  start-page: 6617
  year: 2013
  ident: 3608_CR41
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.448209
– volume: 55
  start-page: 812
  year: 2019
  ident: 3608_CR28
  publication-title: In Vitro Cell Dev Biol Anim
  doi: 10.1007/s11626-019-00398-5
– volume: 325
  start-page: 669
  year: 2021
  ident: 3608_CR9
  publication-title: JAMA
  doi: 10.1001/jama.2021.0106
– volume: 23
  start-page: 7482
  year: 2019
  ident: 3608_CR16
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 4
  start-page: 1151
  year: 2012
  ident: 3608_CR37
  publication-title: Oncol Lett
  doi: 10.3892/ol.2012.928
– volume: 126
  start-page: 2798
  year: 2013
  ident: 3608_CR40
  publication-title: J Cell Sci
– volume: 12
  start-page: 9651
  year: 2019
  ident: 3608_CR27
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S228995
– volume: 144
  start-page: 2290
  year: 2019
  ident: 3608_CR7
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32084
– volume: 6
  start-page: e353
  year: 2017
  ident: 3608_CR14
  publication-title: Oncogenesis
  doi: 10.1038/oncsis.2017.57
– volume: 111
  start-page: 1131
  year: 2019
  ident: 3608_CR8
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djz093
– volume: 278
  start-page: 14657
  year: 2003
  ident: 3608_CR33
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M211285200
– volume: 149
  start-page: 1659
  year: 2021
  ident: 3608_CR6
  publication-title: Int J Cancer
  doi: 10.1002/ijc.33725
– volume: 17
  start-page: 116
  year: 2017
  ident: 3608_CR11
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-017-0490-y
– volume: 70
  start-page: 7
  year: 2020
  ident: 3608_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21590
– volume: 8
  start-page: 509
  year: 2012
  ident: 3608_CR23
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.971
– volume: 109
  start-page: 14128
  year: 2012
  ident: 3608_CR24
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1205246109
– volume: 12
  start-page: 30
  year: 2013
  ident: 3608_CR30
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-12-30
– volume: 149
  start-page: 1098
  year: 2012
  ident: 3608_CR38
  publication-title: Cell
  doi: 10.1016/j.cell.2012.02.065
– year: 2021
  ident: 3608_CR17
  publication-title: Cancers
  doi: 10.3390/cancers13112550
– year: 2020
  ident: 3608_CR31
  publication-title: J Clin Med
  doi: 10.3390/jcm9082419
– volume: 27
  start-page: 329
  year: 2017
  ident: 3608_CR22
  publication-title: Cell Res
  doi: 10.1038/cr.2016.159
– volume: 9
  start-page: 1207
  year: 2019
  ident: 3608_CR29
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.01207
SSID ssj0024549
Score 2.4087458
Snippet Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a...
Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of...
Abstract Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Antibodies
Antigens
Biomarkers
Breast cancer
Cancer
Cancer therapies
Care and treatment
Cell culture
Chromatin
Cloning
Colorectal cancer
Colorectal carcinoma
Gene silencing
Glycolysis
Health aspects
Hexokinase
HK2
Medical prognosis
Membrane proteins
Membrane-associated RING-CH protein 8 (MARCH8)
Membranes
Metabolism
Metastasis
MicroRNA
miR-32
Packaging
Patients
Plasmids
Proteasomes
Proteins
Risk factors
Survival analysis
Tumor proteins
Tumors
Ubiquitin
Ubiquitin-protein ligase
Ubiquitination
Xenografts
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_SQ_EiWhVHq0QQVCQ0HzOZ5NiWlkVYD2Kht5BJMrqwnS27W6H9630vM7N0FPTidZIMyft-5OX3CHknkq2D4hHbt3NsYVYxE6Rlxqbghecq5F6H8y96dlF-vqwu77X6wpqwHh64J9yRsRGcZIO4VKqUwZtGeSkD5BGN1ZVIaH3B543J1IiyB2nP-ETG6KMNeDUwCFi5DhabG3Y3cUMZrf9Pm_x7neQ9x3P-mDwaIkZ63O_0CXmQugOyPx_uxJ-S7TxdQcrbJeYHUqdIscaBnc5ohmFYdPTDHG-FzEe62FBPu9XPtKTfl7cgBYhIQtd9PexqTfvKcPhDc0uvFl-ZkhSWI7Q1mkbYR0AxWT8jF-dn305nbOilwALEZFsmTeDRBB2DD6aKUbRKpAbSiQYSlsiVTUrbFmIbnqytqlZy741uktSyrrWO6jnZ61ZdekEoaHwl2ia1ooT0igfDSwVM8UqXrYipKogYSevCADSO_S6WLiccRrueHQ7Y4TI73F1BPu3WXPcwG3-dfYIc281EiOz8AQTHDYLj_iU4BXmP_HaoyLA9oEv_HgEOiZBY7hixtfI1aEEOJzNBAcN0eJQYNxiAjZM1xqIQXQE53u6GcSUWtXVpdZPnIFiSULIg9UTSJiebjnSLHxkE3EIeD6H7y_9Bilfkocy6YRmvDsnedn2TXkOstW3eZLX6BQyHIq8
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86QXwRP7E6JYKgImH5aNPkSeZwXITrgzi4b6FN0nnhrt1674Ttr_ectPfOKuy1Sdo05yPn15z-DiHvRLSlVzxg-XaOJcwKZry0zNjoK1Fx5VOtw_l3PTvJvy2KxfjBbT2mVW59YnLUofP4jfxAlri5w3ZVfD6_YFg1Ck9XxxIad8k9pC5D8FUubgBXDuBn-6OM0Qdr2NvALWD-Ovhtbtj1ZDNKnP3_e-Z_syX_2n6OH5GHY9xIDwdBPyZ3YvuE3J-PJ-NPyWYezwD4tpFV44LHQDHTgR3NaCJjWLb0wxzPhsxHulzTirbd77iip6sr0AXkJaH9kBXb9XTID4c71Ff0bPmDKUlhOBJco4OEeXhUlv4ZOTn--vNoxsaKCsxDZLZh0ngejNfBV94UIYhGiVgDqKgBtgSubFTaNhDh8GhtUTSSV5XRdZRalqXWQT0ne23XxheEgt0XoqljI3IAWdwbnqtaVZXSeSNCLDIitkvr_Eg3jlUvVi7BDqPdIA4H4nBJHO46I592Y84Hso1be39Bie16IlF2utD1p260O2dsgBirRlozlUtfGZijlB5gaG11IWJG3qO8HZozTA_WZfgrAV4SibHcITJspcPQjOxPeoIZ-mnzVmPc6AbW7kZpM_J214wjMbWtjd1l6oOUSULJjJQTTZu82bSlXf5KVOAW0DwE8C9vf_gr8kAmrbeMF_tkb9NfxtcQS23qN8lg_gBTThsn
  priority: 102
  providerName: ProQuest
Title Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer
URI https://www.proquest.com/docview/2715512015
https://www.proquest.com/docview/2710973132
https://pubmed.ncbi.nlm.nih.gov/PMC9446774
https://doaj.org/article/89d658b0555342ca8b3a22c601b9651e
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9QwFA57AfFFvOLoOkQQfJBoLk2aPIjsLLsMwiwyODD4Eto0XQdnW-3MirO_3pO0M1pd9qUPTdKmOZd8pz39DkKvmDepE7QI5dtpKGEmiXbcEG28y1hGhYu1DifnajxLPs7lfA9tyx11C7i6MbQL9aRmzfLtrx-bD2Dw76PBa_VuBXsWmHvISwd_TDW53keHsDOloZTDJNF_uPdkhMMsSQ2R4Aa2P9HceI3eRhX5_P_32v9mUv61NZ3dR_c6TImPWyV4gPZ89RDdmXRfzR-hbxN_CUFx5UnWCcMXOGRBkJMxjkQNiwovVjjDVf3TL_HFcgPqEahKcNMmytYNblPGYWC-wZeLKREcw6jAeR18JtzeBf1pHqPZ2ennkzHpiiwQB2BtTbh2tNBOFS5zWhYFKwXzOcQZOUQyBRXGC2VKAD3UGyNlyWmWaZV7rniaKlWIJ-igqiv_FGFwBZKVuS9ZAnEXdZomIhdZJlRSssLLAWLbFbWuYyAPhTCWNkYiWtlWChakYKMU7PUAvdmN-d7yb9zaexQEtesZuLPjibq5sJ0pWm0KgF15YDoTCXeZhjly7iAyzY2SzA_Q6yBmG3QOpgfr0v6oAA8ZuLLscSDdit9HB-io1xMs0_Wbt4pit4pteRpAKsAuWI6Xu-YwMmS7Vb6-in0CixITfIDSnoL1nqzfUi2-RnZwAwE-YPpnt8_tObrLo7IbQuUROlg3V_4FwKt1PkT76TwdosPR6fmn6TC-pBhGO4LjdPTlNzBjIsA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiKcIFDASCBCymth52AeE2tJqS7srVLVSb27iOGWlbVKyW9D2R_EbmXGSLQGpt15jO7E973j8DSFvAqsSI_wcy7f7WMIsYtJwxaSyJg1SXxhX63A0jodH4dfj6HiF_O7uwmBaZacTnaLOK4P_yNd5gsYdzFX0-fwHw6pReLraldBo2GLPLn5ByDb7tPsF6PuW853tw60ha6sKMAPeyZxxafxcmjg3qZFRngeFCGwGjnUGrnvuC2VFrAqw8r5VKooK7qepjDPLY54kcZwLeO8tshoKcBUGZHVze_zt4ArdD8Kt7mqOjNdnYE1BEWHGPFgKX7LLnvlzVQL-twX_5mf-ZfB27pN7radKNxrWekBWbPmQ3B61Z_GPyHxkzyDULi1LWxLbnGJuBdsaUgf_MCnp-xGeRskPdDKjKS2rn3ZKT6cL4D5EQqF1k4db1bTJSIc3ZAt6NjlgglMYjpDaqJJhHgbZs35Mjm5kt5-QQVmV9imhoGmioMhsEYQQ1vlG-qHIRJqKOCyC3EYeCbqt1aYFOMc6G1PtAh0Z64YcGsihHTn0pUc-LsecN_Ae1_beRIoteyI0t3tQ1ae6lXQtVQ5eXYZAaiLkJpUwR84NBL6ZiqPAeuQd0lujAoHpwb409yBgkQjFpTcQ08sdv3pkrdcTBN_0mzuO0a3imekrMfHI62UzjsRkutJWF64PgjQFgnsk6XFab2X9lnLy3YGPqxBMaxI-u_7jr8id4eFoX-_vjveek7vcSYBifrRGBvP6wr4AT26evWzFh5KTm5bYP_PFWP4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Membrane-associated+RING-CH+protein+is+a+novel+glycolysis+repressor+targeted+by+miR-32+in+colorectal+cancer&rft.jtitle=Journal+of+translational+medicine&rft.au=Wang%2C+Zhan&rft.au=Wang%2C+Miao-Miao&rft.au=Geng%2C+Yan&rft.au=Ye%2C+Chen-Yang&rft.date=2022-09-05&rft.pub=BioMed+Central+Ltd&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-022-03608-z&rft.externalDocID=A716252954
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon